US Payers’ Perspectives on Digital Therapeutics
About this webinar
The exponential growth of the digital health products industry has brought an array of options for helping patients to prevent, manage and treat medical conditions. A subset of this trend, digital therapeutics, can be used independently or along with medications, devices, or other therapies across a variety of disease states. They also can capture real world data on usage, engagement, disease progression, healthcare outcomes and therapeutic efficiency.
With the increasing adoption of digital tools and the ongoing need to monitor both healthcare costs and the rising incidence in chronic diseases, it is worth asking: Are US payers prepared to evaluate and determine coverage for these products?
Join this free webinar for an overview of the digital health landscape and details from ICON’s in-depth interviews with health plan and pharmacy benefit manager leaders. Attendees will gain insights on what to expect from US payers and how digital health manufacturers can be successful in this rapidly expanding market.
Who should attend
- Digital therapeutics
- Health economics & outcomes research (HEOR)
- Marketing
- Market access
- Medical affairs
- Regulatory affairs
Featured Speakers
Benjamin Schatzman, PharmD
Dr Benjamin Schatzman has over 21 years of managed care pharmacy experience, including PBM and Managed Care. His expertise includes formulary management, medical policy, payer access, health plan pharmacy operations, regulatory and governmental affairs work pertaining to pharmacy, PBM and specialty pharmacy oversight, as well as government-sponsored health plans including Medicaid, Medicare and Health Insurance Exchange. Prior to joining ICON, Dr Schatzman was Vice President of Pharmacy Plan Operations and Clinical Support at Molina Healthcare, a Fortune 500 company, where he helped oversee a $3 billion-plus pharmacy benefit.
Curran Sidhu
Mr Curran Sidhu works with global pharma and medical device clients on projects involving value proposition development, pricing and market access strategy and reimbursement strategy. His experience spans several therapeutic areas including oncology, diabetes, immunology, ophthalmology, and orthopedics.
Partner for this event
ICON
ICON plc is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently operates from 98 locations in 40 countries and has approximately 15,100 employees. Further information is available at ICONplc.com.
Related webinars
More from Icon.
Insights into first-in-human study design of oligonucleotides
When patients lead: Breaking barriers in ultra-rare disease drug development
ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Becoming a sponsor of choice for high-performing sites
Riding the data wave: How pharma can navigate disruptions in open claims
Beyond the bench: The advantages of GMP over USP compounding in early phase development
Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases
Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies
Introducing ICON Strategic Solutions FSP Services: How This Model Supports Sponsors in Korea
From Fragmented to Fluid: A Deep Dive into Claims Data Innovation
Get ready for a new wave of clinical trials in Schizophrenia: how Sites and Sponsors can avoid conceptual mistakes
Implementing digital health technologies for patient-centred trials